Urothelial Carcinoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Pfizer, Merck, Eisai Inc, AstraZeneca, Seagen Inc, Bayer, Incyte Corporation, Acerta Pharma BV

Urothelial Carcinoma emerging therapies such as KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Erdafitinib and Cetrelimab, and others are expected to boost the Urothelial Carcinoma Market in the upcoming years.

DelveInsight has launched a new report on "Urothelial Carcinoma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Urothelial Carcinoma, historical and forecasted epidemiology as well as the Urothelial Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our urothelial carcinoma market sample report @ https://www.delveinsight.com/report-store/urothelial-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Recent advancements in the Urothelial Carcinoma Market:
In May 2022, Exelixis, Inc. released detailed findings from multiple cohorts of the Phase Ib COSMIC-021 trial, evaluating cabozantinib (CABOMETYX^®) both as a monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The company announced plans to present data from Urothelial Carcinoma (UC) cohorts 3, 4, and 5, as well as Non-Small Cell Lung Cancer (NSCLC) cohorts 7 and 20, during oral abstract sessions at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 3-7.
In May 2022, Kinnate Biopharma Inc. unveiled the design and rationale for its Phase I trial-in-progress (KIN-4802, NCT05242822) assessing KIN-3248, a pan-FGFR inhibitor. The company planned to present details during a poster session on June 6, 2022, at the ASCO Annual Meeting.
In April 2022, Ikena Oncology, Inc. announced it would present two trial-in-progress posters at ASCO 2022, providing insights into clinical trials for its TEAD inhibitor, IK-930, and aryl hydrocarbon receptor (AHR) antagonist, IK-175.
In March 2022, Juniper Biologics Pte Ltd and Helsinn Group entered into an exclusive licensing agreement for the development and commercialization of infigratinib (INN) in Australia, New Zealand, Southeast Asia, and select Middle Eastern and African markets. This agreement focuses on treating adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 fusion or other rearrangements.

Some of the key facts of the Urothelial Carcinoma Market Report:

In 2023, the Urothelial Carcinoma market was valued at approximately USD 900 million in the 7MM and is projected to grow by 2034 during the study period (2020-2034).
Urothelial Carcinoma is a type of cancer that originates in the urothelial cells lining the urinary tract. The term "urothelium" refers to the epithelial lining found on the mucosal surfaces of the renal collecting tubules, calyces, pelvis, ureter, bladder, and urethra.
The majority (~90%) of Urothelial Carcinoma cases are Urothelial Bladder Cancer (UBC), while Upper Tract Urothelial Carcinoma (UTUC) accounts for only 5-10% of all urothelial malignancies.
This cancer primarily affects males (70-80%), likely due to the higher prevalence of smoking among men compared to women. Smoking is a significant risk factor, with nearly half of Urothelial Carcinoma cases linked to a history of smoking.
In 2023, the United States had the highest incidence of Urothelial Carcinoma, accounting for approximately 40% of all reported cases.
The risk of developing Urothelial Carcinoma increases with age, with approximately 90% of patients being over 60. This may also be because the disease is often diagnosed at later stages, with around 30% of cases identified at muscle-invasive or metastatic stages.
According to the World Health Organization (2016), bladder cancers are classified based on differentiation, ranging from low grade (grades 1 and 2) to high grade (grade 3). These classifications influence risk assessment and patient management strategies.
Several major pharmaceutical companies, including Johnson & Johnson, AstraZeneca, and Astellas Pharma/Seagen/Merck, are actively engaged in developing treatments for Urothelial Carcinoma. The anticipated introduction of new and emerging therapies is expected to drive substantial market growth throughout the forecast period (2024-2034).
Promising Urothelial Carcinoma pipeline therapies in various stages of development include KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Erdafitinib and Cetrelimab, and others.
To discover more interesting facts on urothelial carcinoma market, visit: https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Urothelial Carcinoma market report:
Urothelial Carcinoma market report covers a descriptive overview and comprehensive insight of the Urothelial Carcinoma Epidemiology and Urothelial Carcinoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Urothelial Carcinoma market report provides insights on the current and emerging therapies.
Urothelial Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Urothelial Carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Urothelial Carcinoma market.

Got queries? Click here to know more about the Urothelial Carcinoma Market Landscape https://www.delveinsight.com/report-store/urothelial-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Urothelial Carcinoma Overview

Urothelial Carcinoma is the most prevalent malignancy of the urinary system, originating from urothelial cells, typically in individuals aged 50 and above. It is more common in males, occurring at a rate two to three times higher than in females.

This cancer is characterized by the infiltration of the basement membrane or lamina propria by urothelial-derived neoplastic cells. The vast majority (90%) of Urothelial Carcinoma cases are Urothelial Bladder Cancer (UBC), while Upper Tract Urothelial Carcinoma (UTUC) accounts for only 5-10% of urothelial malignancies. Key risk factors for both UTUC and UBC include cigarette smoking, occupational exposure to harmful substances, and other contributing environmental and genetic factors.

Urothelial Carcinoma Treatment Market

Approximately 70% of patients are diagnosed with non-muscle-invasive bladder cancer (NMIBC), with 10-30% of cases progressing to invasive disease despite localized treatment. The remaining 30% have muscle-invasive bladder cancer (MIBC), which carries a high risk of metastasis and progression, even after radical surgery and systemic therapy.

The primary treatment approach includes chemotherapy, typically using cisplatin-based regimens. If the disease progresses after initial systemic therapy, immunotherapy, including agents such as atezolizumab and pembrolizumab, provides an alternative treatment option. Surgical procedures like nephroureterectomy may also be performed when necessary.

Chemotherapy has been a cornerstone of Urothelial Carcinoma treatment since the 1970s and 1980s, with various agents demonstrating effectiveness. The standard first-line therapy for advanced or metastatic Urothelial Carcinoma involves platinum-based chemotherapy, including MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) or GC (gemcitabine and cisplatin) regimens.

Urothelial Carcinoma Market Outlook

The dynamics of the Urothelial Carcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies by key companies such as Pfizer, Merck, Eisai Inc, AstraZeneca, Seagen Inc, Bayer, Incyte Corporation, Acerta Pharma BV, and others during the forecast period 2020-2034.

Request for a detailed sample report @ https://www.delveinsight.com/sample-request/urothelial-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Urothelial Carcinoma Marketed Therapies
KEYTRUDA (pembrolizumab): Merck
OPDIVO (nivolumab): Bristol Myers Squibb

Urothelial Carcinoma Emerging Therapies
BT8009: Bicycle Therapeutics
Erdafitinib and Cetrelimab: Johnson & Johnson

Scope of the Urothelial Carcinoma Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Urothelial Carcinoma Companies: Pfizer, Merck, Eisai Inc, AstraZeneca, Seagen Inc, Bayer, Incyte Corporation, Acerta Pharma BV, and others
Key Urothelial Carcinoma Therapies: KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), BT8009, Erdafitinib and Cetrelimab, and others
Urothelial Carcinoma Therapeutic Assessment: Urothelial Carcinoma current marketed and Urothelial Carcinoma emerging therapies
Urothelial Carcinoma Market Dynamics: Urothelial Carcinoma market drivers and Urothelial Carcinoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Urothelial Carcinoma Unmet Needs, KOL's views, Analyst's views, Urothelial Carcinoma Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Urothelial Carcinoma Patient Share (%) Overview at a Glance
5. Urothelial Carcinoma Market Overview at a Glance
6. Urothelial Carcinoma Disease Background and Overview
7. Urothelial Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Urothelial Carcinoma
9. Urothelial Carcinoma Current Treatment and Medical Practices
10. Unmet Needs
11. Urothelial Carcinoma Emerging Therapies
12. Urothelial Carcinoma Market Outlook
13. Country-Wise Urothelial Carcinoma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Urothelial Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Urothelial Carcinoma Market Outlook 2034 https://www.delveinsight.com/report-store/urothelial-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Urothelial Carcinoma Pipeline Insights, DelveInsight

"Urothelial Carcinoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Urothelial Carcinoma market. A detailed picture of the Urothelial Carcinoma pipeline landscape is provided, which includes the disease overview and Urothelial Carcinoma treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.